Vivus Inc (VVUS) 4.25 $VVUS
VIVUS and Auxilium Announce Stendra Label Expansion - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 19, 5:25PM CDT
VIVUS, Inc. (VVUS) and Auxilium Pharmaceuticals, Inc. (AUXL) announced that the FDA has approved Stendra's supplemental new drug application.
Nasdaq stocks posting largest volume increases
AP - Fri Sep 19, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
Most active Nasdaq-traded stocks
AP - Fri Sep 19, 5:02PM CDT
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
Oracle and Concur are big market movers
AP - Fri Sep 19, 3:40PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Friday on the New York Stock Exchange and the Nasdaq Stock Market:
3 Biotechs Investors Should Watch
Brian Orelli, The Motley Fool - Motley Fool - Fri Sep 19, 12:49PM CDT
In the heathcare version of "Where the Money Is", guest Brian Orelli joins regulars Michael Douglass and David Williamson to discuss the state of the healthcare sector. In M&A news, Endo International has made an unsolicited bid to acquire ...
VIVUS Inc. (VVUS) Rises: Stock Adds 12.4% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Sep 19, 8:32AM CDT
VIVUS Inc. (VVUS) was a big mover last session, as the company saw its shares rise more than 12% on the day.
Critical Alerts For FireEye, VIVUS, Ebix, 58.com and Walter Energy Released By InvestorsObserver
PR Newswire - Fri Sep 19, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for FEYE, VVUS, EBIX, WUBA and WLT.
Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent
PR Newswire - Fri Sep 19, 7:15AM CDT
BioTech News Coverage: Progress made as biotech companies release latest developments, patents and results of studies and trials. Companies in focus are: GenSpera Inc. (OTC: GNSZ), Eli Lilly and Company (NYSE: LLY), Gilead Sciences Inc. (NASDAQ: GILD), Celgene Corporation (NASDAQ: CELG) and Arena Pharmaceuticals Inc. (NASDAQ: ARNA)
Market Maker Surveillance Report. MSON, VVUS, CNQR, PIP, CREG, CRRS, Winning Stocks With Lowest Price Friction For Thursday, September 18th 2014
M2 - Fri Sep 19, 4:02AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Thursday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Thursday there were 4944 companies with "abnormal" market making, 2520 companies with positive Friction Factors and 2350 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Thursday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. Misonix Inc (NASDAQ:MSON), Vivus Inc (NASDAQ:VVUS), Concur Technologies Inc (NASDAQ:CNQR), PharmAthene Inc (NYSE
IP), China Recycling Energy Corp (NASDAQ:CREG), Corporate Resource Services Inc (OTC:CRRS). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
Vivus Set to Possibly Pullback After Yesterday's Rally of 12.37%
Comtex SmarTrend(R) - Thu Sep 18, 4:16PM CDT
Vivus (NASDAQ:VVUS) traded in a range yesterday that spanned from a low of $4.21 to a high of $4.82. Yesterday, the shares gained 12.4%, which took the trading range above the 3-day high of $4.07 on volume of 34.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Why VIVUS, Inc. Is Today's Best Biotech Stock
Sean Williams, The Motley Fool - Motley Fool - Thu Sep 18, 12:26PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of VIVUS , a biopharmaceutical company...
FDA OKs faster-acting label for ED drug Stendra
By The Associated Press - AP - Thu Sep 18, 11:21AM CDT
Federal regulators have approved a new label for Vivus' impotence drug, stating that it becomes effective in half the time that the previous label had stated.
Hot Stock: Vivus, Shares Gain 10.8% (VVUS)
Comtex SmarTrend(R) - Thu Sep 18, 10:08AM CDT
Vivus (NASDAQ:VVUS) is one of today's best performing low-priced stocks, up 10.8% to $4.30 on 10.1x average daily volume. Vivus has traded 14.0 million shares thus far today, vs. average volume of 1.4 million shares per day. The stock has outperformed the Dow (10.8% to the Dow's 0.5%) and outperformed the S&P 500 (10.8% to the S&P's 0.4%) during today's trading.
Why VIVUS (VVUS) Stock Is Up Today
at The Street - Thu Sep 18, 9:17AM CDT
Shares of VIVUS (VVUS) were up in morning trading Thursday after the FDA approved the company's erectile dysfunction drug Stendra.
VIVUS and Auxilium Announce FDA Approval of STENDRA sNDA; STENDRA Now First and Only Oral Erectile Dysfunction Treatment Approved to Be Taken Approximately 15 Minutes Before Sexual Activity
Marketwire - Thu Sep 18, 5:01AM CDT
VIVUS, Inc. (NASDAQ: VVUS) and Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for STENDRA® (avanafil). STENDRA is now the only FDA-approved erectile dysfunction (ED) medication indicated to be taken as early as approximately 15 minutes before sexual activity.
VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity
PR Newswire - Thu Sep 18, 5:00AM CDT
VIVUS, Inc. (Nasdaq: VVUS) and Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for STENDRA® (avanafil). STENDRA is now the only FDA-approved erectile dysfunction (ED) medication indicated to be taken as early as approximately 15 minutes before sexual activity.
5 Things Arena Pharmaceuticals, Inc.'s Management Wants You to Know
Brian Orelli, The Motley Fool - Motley Fool - Wed Sep 17, 9:51AM CDT
Arena Pharmaceuticals held a press conference in conjunction with its second-quarter earnings to let investors know what's happening with its obesity drug Belviq and the rest of its pipeline. Below, you'll find five quotes from the call that...
Doc Offers Glimpse Into Arena Pharma Weight-Loss Combination Therapy
at The Street - Tue Sep 16, 8:48AM CDT
Patients lost 12% of their body weight following 12 weeks of treatment with Arena's Belviq plus phentermine.
2 New Diet Drugs Coming Soon?
George Budwell, The Motley Fool - Motley Fool - Sat Sep 13, 1:05PM CDT
America's love of "supersized" everything has helped fuel an out-of-control obesity problem that is having dire consequences on human health and the economy. For instance, the CDC estimates that the annual medical cost of obesity in the U.S., as of...
VIVUS and Auxilium Announce Stendra Label Expansion - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 19, 5:25PM CDT
VIVUS, Inc. (VVUS) and Auxilium Pharmaceuticals, Inc. (AUXL) announced that the FDA has approved Stendra's supplemental new drug application.
Nasdaq stocks posting largest volume increases
AP - Fri Sep 19, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
Most active Nasdaq-traded stocks
AP - Fri Sep 19, 5:02PM CDT
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
Oracle and Concur are big market movers
AP - Fri Sep 19, 3:40PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Friday on the New York Stock Exchange and the Nasdaq Stock Market:
3 Biotechs Investors Should Watch
Brian Orelli, The Motley Fool - Motley Fool - Fri Sep 19, 12:49PM CDT
In the heathcare version of "Where the Money Is", guest Brian Orelli joins regulars Michael Douglass and David Williamson to discuss the state of the healthcare sector. In M&A news, Endo International has made an unsolicited bid to acquire ...
VIVUS Inc. (VVUS) Rises: Stock Adds 12.4% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Sep 19, 8:32AM CDT
VIVUS Inc. (VVUS) was a big mover last session, as the company saw its shares rise more than 12% on the day.
Critical Alerts For FireEye, VIVUS, Ebix, 58.com and Walter Energy Released By InvestorsObserver
PR Newswire - Fri Sep 19, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for FEYE, VVUS, EBIX, WUBA and WLT.
Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent
PR Newswire - Fri Sep 19, 7:15AM CDT
BioTech News Coverage: Progress made as biotech companies release latest developments, patents and results of studies and trials. Companies in focus are: GenSpera Inc. (OTC: GNSZ), Eli Lilly and Company (NYSE: LLY), Gilead Sciences Inc. (NASDAQ: GILD), Celgene Corporation (NASDAQ: CELG) and Arena Pharmaceuticals Inc. (NASDAQ: ARNA)
Market Maker Surveillance Report. MSON, VVUS, CNQR, PIP, CREG, CRRS, Winning Stocks With Lowest Price Friction For Thursday, September 18th 2014
M2 - Fri Sep 19, 4:02AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Thursday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Thursday there were 4944 companies with "abnormal" market making, 2520 companies with positive Friction Factors and 2350 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Thursday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. Misonix Inc (NASDAQ:MSON), Vivus Inc (NASDAQ:VVUS), Concur Technologies Inc (NASDAQ:CNQR), PharmAthene Inc (NYSE
IP), China Recycling Energy Corp (NASDAQ:CREG), Corporate Resource Services Inc (OTC:CRRS). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net . Vivus Set to Possibly Pullback After Yesterday's Rally of 12.37%
Comtex SmarTrend(R) - Thu Sep 18, 4:16PM CDT
Vivus (NASDAQ:VVUS) traded in a range yesterday that spanned from a low of $4.21 to a high of $4.82. Yesterday, the shares gained 12.4%, which took the trading range above the 3-day high of $4.07 on volume of 34.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Why VIVUS, Inc. Is Today's Best Biotech Stock
Sean Williams, The Motley Fool - Motley Fool - Thu Sep 18, 12:26PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of VIVUS , a biopharmaceutical company...
FDA OKs faster-acting label for ED drug Stendra
By The Associated Press - AP - Thu Sep 18, 11:21AM CDT
Federal regulators have approved a new label for Vivus' impotence drug, stating that it becomes effective in half the time that the previous label had stated.
Hot Stock: Vivus, Shares Gain 10.8% (VVUS)
Comtex SmarTrend(R) - Thu Sep 18, 10:08AM CDT
Vivus (NASDAQ:VVUS) is one of today's best performing low-priced stocks, up 10.8% to $4.30 on 10.1x average daily volume. Vivus has traded 14.0 million shares thus far today, vs. average volume of 1.4 million shares per day. The stock has outperformed the Dow (10.8% to the Dow's 0.5%) and outperformed the S&P 500 (10.8% to the S&P's 0.4%) during today's trading.
Why VIVUS (VVUS) Stock Is Up Today
at The Street - Thu Sep 18, 9:17AM CDT
Shares of VIVUS (VVUS) were up in morning trading Thursday after the FDA approved the company's erectile dysfunction drug Stendra.
VIVUS and Auxilium Announce FDA Approval of STENDRA sNDA; STENDRA Now First and Only Oral Erectile Dysfunction Treatment Approved to Be Taken Approximately 15 Minutes Before Sexual Activity
Marketwire - Thu Sep 18, 5:01AM CDT
VIVUS, Inc. (NASDAQ: VVUS) and Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for STENDRA® (avanafil). STENDRA is now the only FDA-approved erectile dysfunction (ED) medication indicated to be taken as early as approximately 15 minutes before sexual activity.
VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity
PR Newswire - Thu Sep 18, 5:00AM CDT
VIVUS, Inc. (Nasdaq: VVUS) and Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for STENDRA® (avanafil). STENDRA is now the only FDA-approved erectile dysfunction (ED) medication indicated to be taken as early as approximately 15 minutes before sexual activity.
5 Things Arena Pharmaceuticals, Inc.'s Management Wants You to Know
Brian Orelli, The Motley Fool - Motley Fool - Wed Sep 17, 9:51AM CDT
Arena Pharmaceuticals held a press conference in conjunction with its second-quarter earnings to let investors know what's happening with its obesity drug Belviq and the rest of its pipeline. Below, you'll find five quotes from the call that...
Doc Offers Glimpse Into Arena Pharma Weight-Loss Combination Therapy
at The Street - Tue Sep 16, 8:48AM CDT
Patients lost 12% of their body weight following 12 weeks of treatment with Arena's Belviq plus phentermine.
2 New Diet Drugs Coming Soon?
George Budwell, The Motley Fool - Motley Fool - Sat Sep 13, 1:05PM CDT
America's love of "supersized" everything has helped fuel an out-of-control obesity problem that is having dire consequences on human health and the economy. For instance, the CDC estimates that the annual medical cost of obesity in the U.S., as of...
